national
FDA Grants Approval for Advanced Pancreatic Cancer Treatment Daraxonrasib
Just the facts
The U.S. Food and Drug Administration approved daraxonrasib, a first-in-class oral medication designed to treat advanced pancreatic cancer by inhibiting specific proteins that drive tumor growth. Clinical trial data showed that patients treated with daraxonrasib recorded a median overall survival of 13.2 months, compared to 6.7 months for patients receiving standard chemotherapy. Medical researchers characterized the targeted mechanism as a significant therapeutic advancement for a historically difficult-to-treat form of cancer. The decision permits healthcare providers nationwide to begin prescribing the drug to eligible oncology patients.
Why this is news
The U.S. Food and Drug Administration issued regulatory approval for a novel oral therapy targeting pancreatic cancer.
Sources
This summary is compiled strictly from the original reporting below.